Skeletal muscle interleukin 15 promotes CD8+ T-cell function and autoimmune myositis by Po-Lin Huang et al.
RESEARCH Open Access
Skeletal muscle interleukin 15 promotes
CD8+ T-cell function and autoimmune myositis
Po-Lin Huang1,2, Mau-Sheng Hou2, Szu-Wen Wang2, Chin-Ling Chang2, Yae-Huei Liou2 and Nan-Shih Liao1,2*
Abstract
Background: Interleukin 15 (IL-15) is thought to be abundant in the skeletal muscle under steady state conditions
based on RNA expression; however, the IL-15 RNA level may not reflect the protein level due to post-transcriptional
regulation. Although exogenous protein treatment and overexpression studies indicated IL-15 functions in the skeletal
muscle, how the skeletal muscle cell uses IL-15 remains unclear. In myositis patients, IL-15 protein is up-regulated in the
skeletal muscle. Given the supporting role of IL-15 in CD8+ T-cell survival and activation and the pathogenic role of
cytotoxic CD8+ T cells in polymyositis and inclusion-body myositis, we hypothesize that IL-15 produced by the
inflamed skeletal muscle promotes myositis via CD8+ T cells.
Methods: Expression of IL-15 and IL-15 receptors at the protein level by skeletal muscle cells were examined under
steady state and cytokine stimulation conditions. The functions of IL-15 in the skeletal muscle were investigated using
Il15 knockout (Il15−/−) mice. The immune regulatory role of skeletal muscle IL-15 was determined by co-culturing
cytokine-stimulated muscle cells and memory-like CD8+ T cells in vitro and by inducing autoimmune myositis in
skeletal-muscle-specific Il15−/− mice.
Results: We found that the IL-15 protein was not expressed by skeletal muscle cells under steady state condition but
induced by tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) stimulation and expressed as IL-15/IL-15
receptor alpha (IL-15Rα) complex. Skeletal muscle cells expressed a scanty amount of IL-15 receptor beta (IL-15Rβ)
under either conditions and only responded to a high concentration of IL-15 hyperagonist, but not IL-15. Consistently,
deficiency of endogenous IL-15 affected neither skeletal muscle growth nor its responses to TNF-α and IFN-γ. On the
other hand, the cytokine-stimulated skeletal muscle cells presented antigen and provided IL-15 to promote the effector
function of memory-like CD8+ T cells. Genetic ablation of Il15 in skeletal muscle cells greatly ameliorated autoimmune
myositis in mice.
Conclusions: These findings together indicate that skeletal muscle IL-15 directly regulates immune effector cells but
not muscle cells and thus presents a potential therapeutic target for myositis.
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Background
Interleukin 15 (IL-15) is widely expressed as its high-
affinity binding partner IL-15 receptor alpha (IL-15Rα)
at the RNA level, and the expression of IL-15 is sub-
jected to multiple post-transcriptional regulations [1].
Newly synthesized IL-15 and IL-15Rα proteins form
complex in the endoplasmic reticulum [2, 3]. The com-
plex is transported to and displayed on the cell surface
and used via the IL-15 receptor beta (IL-15Rβ) and the
common gamma chain (γc) expressed on neighboring
cells [4, 5]. The binding of IL-15/IL-15Rα complex to IL-
15Rβ/γc on the responding cells triggers the activation of
JAK-STAT3/5, phosphatidylinositol 3-kinase (PI3K)-AKT,
and p42/44 mitogen-activated protein kinase (ERK) sig-
naling pathways [6, 7]. This mode of IL-15 usage termed
“trans-presentation” is essential for the development and
homeostasis of memory CD8+ T cells, CD8αα+ intestinal
intraepithelial T cells, and natural killer (NK) cells [8].
Notably, all naturally produced IL-15 proteins detected in
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human and mouse serum and in activated dendritic cells
are in complex with IL-15Rα [3, 9].
IL-15 has been thought of as a myokine due to the
abundant mRNA expression in the skeletal muscle [10].
Moreover, expression of Il15 mRNA is up-regulated along
myoblast differentiation [11]. Previous studies showed that
exogenous treatment or overexpression of IL-15 promotes
myoblast differentiation and muscle hypertrophy and
ameliorates muscle wasting in cancer cachexia [12–16].
Whereas skeletal-muscle-specific overexpression or sys-
temic infusion of IL-15 induces skeletal muscle atrophy in
vivo [17–19]. Moreover, recent studies showed that exer-
cise endurance is reduced in Il15−/− mice and increased in
skeletal-muscle-specific Il15-transgenic mice [18, 20].
However, the extensor digitorum longus (EDL) and soleus
muscle isolated from these two types of genetically engi-
neered mice show similar fatigue index ex vivo [21].
Therefore, the function of IL-15 in the skeletal muscle
under non-disease conditions remains elusive.
Inflammatory myopathies are a group of diseases that
involve chronic muscle inflammation (myositis) accom-
panied with muscle weakness [22]. The three main types
including polymyositis, dermatomyositis, and inclusion
body myositis are classified based on distinct clinicopatho-
logical features. They are idiopathic, but an autoimmune
pathogenesis is strongly implicated. Dermatomyositis is
mediated by complement, while polymyositis and inclu-
sion-body myositis is mediated by CD8+ T cells that
target major histocompatibility complex (MHC) class-I-
expressing muscle cells through secreting cytotoxic ef-
fector molecules [23–25]. Interferon alpha (IFN-α),
interferon gamma (IFN-γ), tumor necrosis factor alpha
(TNF-α), and IL-1α/β are up-regulated in the muscle of
myositis patients, which is implicated in the mediation
of Th1 and pro-inflammatory responses [26]. Stimula-
tion of myoblasts with IL-1α/β, TNF-α, or IFN-γ in-
duces IL-15 production in vitro [27, 28]. Consistently,
elevation of IL-15 protein has been observed in the
skeletal muscle of myositis patients [27, 28]. Local up-
regulation of IL-15 in certain autoimmune diseases posi-
tively associates with disease severity. An increase of IL-15
protein in the intestinal mucosa and synovial cavity of ce-
liac disease and rheumatoid arthritis patients, respectively,
stimulates dendritic cells, NK cells, and effector T cells to
exacerbate the disease [29, 30]. However, the role of skel-
etal muscle IL-15 in myositis has not been reported. Given
the essential role of IL-15 in memory CD8+ T-cell survival
and function and the pathogenic role of cytotoxic CD8+ T
cells in polymyositis and inclusion-body myositis, we
hypothesize that the skeletal muscle IL-15 promotes auto-
reactive CD8+ T-cell function, which contributes to the
development of autoimmune myositis.
Considering that the level of IL-15 RNA may not
reflect the level of protein due to post-transcriptional
regulations [31] and that the usage of IL-15 by skeletal
muscle cells has not been studied, we examined the ex-
pression of IL-15 and its receptors at the protein level in
skeletal muscle cells under steady state and cytokine-
stimulated conditions. We then examined the function
of endogenous IL-15 in the skeletal muscle cell and its
role in the development of autoimmune myositis.
Methods
Mice
C57BL/6J, B6.Cg-Tg(ACTA1-cre)79Jme/J (human alpha-
skeletal actin (ACTA)-cre), and B6.129S1-synaptotagmin
VII (Syt7)tm1Nan/J (Syt7−/−) were purchased from The
Jackson Laboratory (Bar Harbor, ME). Il15−/− mice were
purchased from Taconic and backcrossed to the C57BL/
6J for at least 14 generations. Il15ra−/− mice were devel-
oped in our laboratory and backcrossed to the C57BL/6J
for 27 generations [32]. Il15flox/flox (Il15f/f ) mice were
generated in our laboratory as previously described [33].
Skeletal-muscle-specific Il15−/− (ACTA-Il15−/−) mice
were generated by crossing Il15f/f with ACTA-cre mice.
All experimental procedures were performed in accord-
ance with protocols approved by the Institutional Animal
Care and Use Committee of Academia Sinica.
Culture of skeletal muscle cells
C2C12 myoblasts were maintained in Dulbecco’s modi-
fied Eagle’s medium (DMEM) containing 10 % fetal
bovine serum (FBS). Confluent C2C12 myoblasts were
shifted to differentiation medium (DMEM containing
2 % horse serum) for myotube differentiation. Unless in-
dicated otherwise (Fig. 1a), C2C12 myotubes were used
4 days after differentiation induction, when about 80 %
of culture plate surface was covered by myotubes. Pri-
mary myoblasts were isolated from the limb muscle of
1- to 3-day-old neonatal mice and purified by sorting of
α7 integrin-positive cells as previously described [34].
Rat anti-α7 integrin monoclonal antibody, CA5.5, was
kindly provided by Dr. Chung-Chen Yao (National
Taiwan University). Purified primary myoblasts (about
25,000 cells/cm2) were cultured in growth medium
(40 % Ham’s F-10, 40 % DMEM, 20 % FBS, 2.5 ng/ml
bFGF) for 1 day and then switched to differentiation
medium (DMEM containing 5 % horse serum). Some
primary myoblasts already fused to form nascent myo-
tubes during the 1-day culture in growth medium. After
changing to differentiation medium, well-differentiated
primary myotubes appeared in day 1 and were used for
experiments in day 2.
Measurement of IL-15/IL-15Rα complex protein
Cells or skeletal muscle tissues were homogenized in non-
denaturing cell lysis buffer (Cell signaling) containing
protease inhibitor cocktail (Roche). For quantification of
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surface IL-15Rα-bound IL-15, muscle cells were incubated
with acid glycine buffer as previously described [35]. The
amount of IL-15/IL-15Rα complex was measured by
mouse IL-15/IL-15Rα Complex ELISA Kit (eBioscience).
Western blotting
To study signal transduction, adherent cells were washed,
and a fixed volume of sodium dodecyl sulfate (SDS) sample
buffer (50 mM Tris-Cl, pH 6.8, 6 % glycerol, 0.02 % bro-
mophenol blue, 2 % SDS, and 2 % β-mercaptoethanol) was
directly added to culture wells. Immunoblotting was per-
formed using anti-p-STAT5 and t-STAT5 antibodies (Cell
signaling) following the protocol of antibody manufacturer.
Gene expression analysis by quantitative real-time PCR
(qPCR)
Total RNA was extracted by TRIzol, treated with DNase
I, then reverse transcribed into cDNA by SuperScript III
reverse transcriptase (Invitrogen, Life Technologies).
Quantitative PCR was performed by Applied Biosystems
7500 Real-Time System using SYBR Green Master Mix.
Relative gene expression levels were calculated by ABI
7500 software using acidic ribosomal phosphoprotein P0
(36B4) as the internal control. Primer pairs were pre-
designed in PrimerBank [36] or designed by Primer Express
software (Life Technologies) and are listed in Additional








Fig. 1 Skeletal muscle cells express IL-15/IL-15Rα protein complex in response to TNF-α and IFN-γ stimulation. a Expression of Il15 and Il15ra
mRNA during C2C12 myoblast differentiation. Samples were collected before (0) and 2, 4, and 6 days after differentiation induction. b Expression
of Il15 and Il15ra mRNA in C2C12 myotubes treated with TNF-α (10 ng/ml), IFN-γ (10 ng/ml), TNF-α + IFN-γ (TNF + IFN, 10 ng/ml each), or without
cytokine (con) for 1, 2, 3, 6, 12, and 24 h. c Expression of Il15 and Il15ra mRNA in primary myotubes treated with TNF-α (5 ng/ml), IFN-γ (5 ng/ml),
TNF + IFN (5 ng/ml each), or without cytokine (con) for 24 h. d Expression of IL-15/IL-15Rα complex protein in C2C12 myoblasts and myotubes
treated with TNF-α (1 or 10 ng/ml), IFN-γ (1 or 10 ng/ml), TNF + IFN (1 or 10 ng/ml each), or without cytokine (con) for 24 h. e Expression of IL-
15/IL-15Rα complex protein in primary myotubes treated with TNF + IFN (5 ng/ml each) or vehicle (con) for 24 h. f Expression of IL-15/IL-15Rα
complex protein in skeletal muscle in vivo. TNF-α plus IFN-γ (1 mg each/injection) or PBS (con) was injected into the quadriceps muscles of mice
three times at 4-h intervals. The injected muscles were collected 16 h after the last injection. Total RNA was isolated and analyzed by qPCR (a–c).
Protein lysate and cell culture medium were collected and measured by ELISA (d–f). Data in (a–c) were triplicates and representative of
two independent experiments with similar result. Data in (d, e) were pooled from three independent experiments. Data in (f) was pooled
from three mice in each group. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, in comparison to “0” or “con”
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Co-culture of C2C12 cells with CD8+ T cells
The H-2Kb (NM_001001892) coding sequence (nt. 77-
1186) was cloned from the cDNA library of primary
myotubes of C57BL/6J mice and then inserted into the
EcoRI cloning site of lentiviral package plasmid pLKO
AS3.1.EGFP3′. The full-length ovalbumin (OVA) cDNA
with restriction enzyme cutting sites, 5′-NheI and 3′-
EcoRI, was amplified by PCR from pcDNA3/OVA plasmid
(kindly provided by Dr. Mi-Hua Tao, Academia Sinica)
and inserted into lentiviral package plasmid pLAS2-
w.Ppuro. All lentiviral packaging plasmids and protocols
were from the RNAi Core Facility, Academia Sinica. The
EGFP-positive C2C12 myoblasts were sorted and subse-
quently infected with lentivirus-carrying OVA expression
cassette and selected in growth medium containing 2 μg/
ml puromycin (Sigma). The expression of H-2Kb and OVA
was confirmed by flow cytometry and quantitative real-
time PCR (qPCR), respectively. For CD8+ T cells, spleno-
cytes of OT-1 mice were stimulated with OVA peptide as
previously described [37] then cultured in medium contain-
ing IL-15 (30 ng/ml, eBioscience). After culturing for 8 days,
more than 90 % of cells were CD8+CD44hiCD122hi, and
these cells were used for experiments. C2C12 cells were
treated with TNF-α and IFN-γ (1 ng/ml each) for 24 h.
After washing with PBS, 24-h IL-15-deprived CD8+ T
cells and 5 μg/ml brefeldin A (Sigma) were added sim-
ultaneously to C2C12 cells, followed by brief centrifu-
gation to make the cell-cell contact. CD8+ T cells were
harvested for intracellular cytokine analysis after co-
culturing for 8 h.
Flow cytometry analysis
Lymphocyte surface markers were stained with antibodies
against CD19 (6D5), H57 (H57-597), CD8 (53-6.7), CD44
(IM7), CD122 (TM-b1), and NK1.1 (PK136) (eBioscience
and BioLegend). C2C12 cells were stained with biotin-
conjugated antibodies against IL-15 (Cat. No. 500-P173Bt,
PeproTech), IL-15Rα (Cat. No. BAF551, R&D), IL-15Rβ
(CD122, clone: TM-b1, eBioscience), and γc (CD132, Cat.
No. 554470, BD Biosciences) then incubated with
APC-conjugated streptavidin (BD Biosciences). CD8+
T cells were stained with fixable viable dye eFluor506
(eBioscience) then intracellularly stained with anti-
bodies against IFN-γ (XMG1.2, eBioscience) and gran-
zyme B (NGZB, eBioscience). All data were acquired
on LSRII (BD Biosciences) and analyzed by the
FlowJo (Tree Star).
Induction of experimental autoimmune myositis
Preparation of mouse fast-type skeletal muscle myosin-
binding protein C (C protein) fragment and induction of
myositis were done as previously described with little
modification [38]. C protein fragment purified from
Escherichia coli lysates was washed with 60 % isopropanol
solution to remove endotoxin as previously described [39].
Female mice, 8–10 weeks old, were intradermally im-
munized with 200 μg C protein emulsified in 200 μl
complete Freund’s adjuvant (Sigma-Aldrich) at foot-
pads, back, and tail base. Simultaneously, 0.5 μg pertus-
sis toxin (Calbiochem) was intraperitoneally injected.
The quadriceps muscle was harvested for histology and
gene expression analysis 14 days after immunization.
Each muscle block was cut into four sections with in-
tervals of at least 200 μm. Histopathologic scoring was
based on the most severe inflammation observed in the
section among four sections and graded as previously
described [38].
Statistics
Results were represented as mean ± SEM. Statistical signifi-
cance was determined by unpaired, two-tailed, Student’s t-
test using GraphPad Prism 5 (GraphPad, San Diego, CA).
p values less than 0.05 were considered significant.
Results
Skeletal muscle cells express IL-15/IL-15Rα complex
protein in response to TNF-α and IFN-γ stimulation
Previous studies found up-regulation of Il15 RNA during
myoblast differentiation [11] and pro-inflammatory cyto-
kine stimulation [27]. Given the presence of post-
transcriptional regulation of IL-15 expression and that
all circulating IL-15 are in complex with IL-15Rα [9], we
examined the expression of IL-15/IL-15Rα complex pro-
tein by skeletal muscle cell under the two conditions
mentioned above. During a 6-day C2C12 myoblast-to-
myotube differentiation, the cells showed a greater than
10-fold and a 3-fold increase of Il15 and Il15ra mRNA,
respectively (Fig. 1a), whereas the cell lysate and culture
medium contained no detectable IL-15/IL-15Rα protein
by ELISA with a sensitivity of 3.9 pg/ml. This result indi-
cates that although the level of Il15 and Il15ra mRNA
increased along myoblast-to-myotube differentiation,
there was little production of IL-15/IL-15Rα protein. We
next examined whether pro-inflammatory cytokines in-
duce IL-15 and IL-15Rα expression by skeletal muscle
cells. We found that TNF-α and IFN-γ each up-
regulated Il15 and Il15ra mRNA in C2C12 myotubes
with distinct kinetics and together exerted a synergistic
effect (Fig. 1b). A similar synergistic effect occurred in
primary myotubes (Fig. 1c). TNF-α and IFN-γ treatment
also up-regulated the expression of the IL-15/IL-15Rα
complex protein in C2C12 myoblasts and myotubes
(Fig. 1d) and in primary myotubes (Fig. 1e) in vitro.
Most of the IL-15/IL-15Rα proteins were present in the
C2C12 cell lysates (Fig. 1d), while nearly all IL-15/IL-
15Rα proteins were present in the primary myotube lys-
ate (Fig. 1e). Injection of TNF-α and IFN-γ into the
quadriceps muscle in mice also greatly induced the
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expression of IL-15/IL-15Rα protein in the injected
muscle (Fig. 1f ).
IFN-α, another cytokine up-regulated in myositis
muscle [26], induced Il15 and Il15ra mRNA and IL-15/
IL-15Rα complex protein to the level similar to those in-
duced by IFN-γ or TNF-α (Additional file 2: Figure S1).
Other pro-inflammatory factors, such as IL-1α, IL-1β,
and LPS, only transiently up-regulated Il15ra or Il15
mRNA but showed small effect on the induction of the
IL-15/IL-15Rα protein (Additional file 2: Figure S1). To-
gether, these results indicate that the expression of the
IL-15/IL-15Rα complex protein by skeletal muscle cells
was undetectable under steady state conditions, while in-
duced by TNF-α, IFN-γ, or IFN-α that associates with
Th1 response in myositis.
IL-15 is present on the surface of skeletal muscle cells
As the majority of the cytokine-induced IL-15/IL-15Rα
complex was in the lysates of the myoblast and myotube
(Fig. 1d, e), we next examined whether the complex is
present on the cell surface. We found that TNF-α and
IFN-γ induced expression of IL-15 and IL-15Rα on the
surface of C2C12 myoblasts as detected by flow cytome-
try (Fig. 2a). For the cytokine-treated C2C12 myotubes,
dissociation of IL-15 from IL-15Rα on the cell surface
by washing cells with acidic glycine buffer resulted in an
80 % reduction of IL-15/IL-15Rα in the cell lysate
(Fig. 2b), indicating that 80 % of IL-15 was presented by
IL-15Rα on the cell surface. This reduction was not due
to alteration of IL-15Rα by the acid treatment, as the level
of IL-15/IL-15Rα resumed following the addition of ex-
ogenous IL-15 (Fig. 2b). These results indicated that the
majority of the cytokine-induced IL-15 was present on the
surface of skeletal muscle cells as IL-15/IL-15Rα complex.
Skeletal muscle cells express a scanty amount of IL-
15Rβ and only respond to a high concentration of IL-
15 hyperagonist, but not IL-15
Despite of various reported IL-15 functions in the skel-
etal muscle [12–16], the IL-15-induced signals in skeletal
muscle cells remains unexplored. We first examined the
expression of IL-15Rβ and γc on C2C12 myoblasts by
flow cytometry and detected no IL-15Rβ expression but
a low level of γc induced by TNF-α and IFN-γ treatment
(Fig. 3a). The more sensitive qPCR also detected induc-
tion of γc mRNA, but not Il15rb mRNA, in C2C12 and
primary myotubes by the cytokines (Fig. 3b). Moreover,
the level of Il15rb mRNA in the primary myotube was
16 times lower than that in the C2C12 myotube based
on the Ct value of qPCR.
Due to the possibility of a very low level of IL-15Rβ
expression, we examined whether IL-15 or an IL-15
hyperagonist induces signal transduction in C2C12 myo-
tubes. The latter is a fusion protein of IL-15 and IL-15Rα-
sushi domain, which possesses higher binding affinity for
IL-15Rβ/γc (Kd = 780 pM) and promotes a stronger prolif-
eration of IL-15Rβ/γc-bearing cells (EC50 = 25 pM) than
IL-15 (Kd = 13.5 nM, EC50 = 3 nM) [40]. We found that
IL-15 did not induce STAT5 phosphorylation at a concen-
tration up to 400 ng/ml (26.7 nM) (Fig. 3c). Whereas the
IL-15 hyperagonist induced moderate but significant
STAT5 phosphorylation at concentrations of 100 ng/ml
(3.4 nM) and higher (Fig. 3c), which are much higher than
that required for the proliferation of IL-15Rβ/γc-bearing
cells (EC50 = 25 pM) and for STAT5 phosphorylation in
pre-activated murine CD8+ cells (EC50 = 10 pM) [40, 41].
In addition to STAT5 phosphorylation, IL-15 and IL-15
hyperagonist did not induce phosphorylation of STAT3,
AKT, and ERK in skeletal muscle cells (data not shown).











C2C12 myoblast C2C12 myotube
Fig. 2 IL-15 is presented on the surface of skeletal muscle cells. a Expression of IL-15 and IL-15Rα on C2C12 myoblasts. Cells were treated with
TNF-α and IFN-γ (TNF + IFN) or without cytokine (Control) for 24 h and then stained with anti-IL-15 and IL-15Rα antibodies for flow cytometry analysis.
“Unstained” indicates cells without antibody staining. Data are representative of three independent experiments with similar results. b Quantification of
IL-15 bound by cell surface IL-15Rα on C2C12 myotubes. C2C12 myotubes were first treated with TNF-α and IFN-γ for 24 h, incubated with acid glycine
buffer to dissociate IL-15 from cell surface IL-15Rα, and then re-treated with exogenous IL-15. Cell lysates from each step were collected and the
amount of IL-15/ IL-15Rα complex was measured by ELISA. Data are mean ± SEM of triplicates and representative of two independent experiments
with similar results. ***p < 0.001
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Fig. 3 (See legend on next page.)
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Fig. 4 IL-15 deficiency does not affect the responses of primary myotube to TNF-α and IFN-γ stimulation. a–c Expression profiling of genes involved in
the regulation of skeletal muscle mass and immune system in wt and Il15−/− primary myotubes. Samples were collected 24 h after TNF-α and IFN-γ
treatment and analyzed by qPCR. Data are mean ± SEM of triplicates. Data are representative of two independent experiments with similar results.
*p < 0.05, **p < 0.01, ***p < 0.001
(See figure on previous page.)
Fig. 3 High concentration of IL-15 hyperagonist, but not IL-15, induces STAT5 signaling and atrophy in skeletal muscle cells. a Analysis of IL-15Rβ
and γc expression on C2C12 myoblasts under the same condition of Fig. 2a. Data are representative of three independent experiments with similar
results. b Expression of Il15rb and γc mRNA in C2C12 and primary myotube. Samples were collected 24 h after cytokine treatment and analyzed by
qPCR. Data are triplicates and representative of two independent experiments with similar results. c Immunoblotting of STAT5 phosphorylation in
C2C12 myotubes after treating with IL-15 or IL-15 hyperagonist for 30 min. Quantification data of four independent experiments are shown below. d
Anti-IL-15Rβ antibody diminished IL-15 hyperagonist-induced STAT5 phosphorylation in C2C12 myotubes. Myotubes were pretreated with anti-IL-15Rβ
or isotype control antibody for 1 h and then treated with IL-15 hyperagonist for 30 min. Data are representative of two independent experiments
with similar results. e Immunoblotting of STAT5 phosphorylation in C2C12 myotubes that were first stimulated with TNF-α and IFN-γ for
24 h and then treated with exogenous IL-15 or IL-15 hyperagonist for 30 min. Data are representative of two independent experiments with
similar results. f Accumulation of myosin heavy chain (MyHC) in C2C12 myotubes treated with IL-15 (50 and 100 ng/ml), IL-15 hyperagonist (50 and
100 ng/ml), or vehicle (0 ng/ml). After 48 h, cells were immunostained with FITC-labeled anti-myosin antibody to evaluate the accumulation of MyHC.
MyHC-positive area per microscopic field are shown in the right panel and represented as the percentages of con. Quantification data were pooled
from three independent experiments. Each symbol represents the quantification data from one microscopic field. Scale bar = 500 μm. Data are mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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was completely blocked by the IL-15Rβ-blocking anti-
body TM-b1 (Fig. 3d). However, neither IL-15 nor IL-
15 hyperagonist induced STAT5 phosphorylation in
C2C12 myotubes pre-treated with TNF-α and IFN-γ
(Fig. 3e), which is in line with the decrease of Il15rb
mRNA after cytokine treatment (Fig. 3b). Consistent
with the STAT5 phosphorylation results (Fig. 3c),
100 ng/ml of IL-15 hyperagonist, but not IL-15,
induced atrophy of C2C12 myotubes (Fig. 3f ). In
summary, C2C12 and primary skeletal muscle cells
expressed a scanty IL-15Rβ under steady state condi-
tion and TNF-α/IFN-γ stimulation and only responded
to a high concentration of IL-15 hyperagonist, but not
IL-15. Moreover, we found that Il15−/− mice showed nor-
mal skeletal muscle mass (Additional file 3: Figure S2),
myoblast differentiation (Additional file 4: Figure S3),
cardiotoxin-induced muscle regeneration (Additional file
5: Figure S4), and compensatory hypertrophy of plantaris
muscle (Additional file 6: Figure S5). The in vitro and in
vivo results collectively suggest that the skeletal muscle
cells do not use IL-15.
IL-15 deficiency does not affect the response of primary
myotube to TNF-α and IFN-γ stimulation
As TNF-α and IFN-γ induced abundant expression of
IL-15/IL-15Rα on skeletal muscle cells, the local con-
centration of IL-15/IL-15Rα trans-presentation may be
high enough to trigger signaling through the limited
number of IL-15Rβ/γc on adjacent muscle cells. We
thus examined whether IL-15 affects the response of
the skeletal muscle to TNF-α and IFN-γ by comparing
wild type (wt) and Il15−/− primary myotubes. As TNF-α
and IFN-γ induce muscle wasting under cancer cach-
exia and IL-15 was shown to prevent it [16, 42, 43], we
first examined genes that regulate muscle mass. Upon
TNF-α and IFN-γ stimulation, wt and Il15−/− primary
myotubes showed similar reduction in the hypertrophy-
related genes Igf1 and Myh4 and increase in the
atrophy-related gene iNos (Fig. 4a). We next examined
the immune regulatory genes affected by IL-15 in im-
mune cells [44–48]. We found that TNF-α and IFN-γ
induced the expression of immune regulatory genes in
wt and Il15−/− primary myotubes to similar extents,
including molecules in the MHC class I antigen
presentation pathway and for T-cell co-stimulation and
inhibition, chemokines, and cell adhesion molecules
(Fig. 4b, c). These results indicate that skeletal muscle
IL-15 does not affect the expression of protein
homeostasis and immune regulation genes by skeletal
muscle cells in response to TNF-α and IFN-γ, which
is consistent with the idea that the muscle cells do
not use their own IL-15.
Skeletal muscle cells stimulated with TNF-α and IFN-γ
present antigen and provide IL-15 to memory-like CD8+
T cells
IL-15 is a well-known survival and activation factor for
memory CD8+ T cells. As inflammatory cytokines induce
the expression of IL-15/IL-15Rα and antigen presenta-
tion molecules by myoblasts and myotubes [49], we de-
signed a muscle-cell-T-cell co-culture system to assess
whether the muscle cells directly activate CD8+ T cells
and the role of IL-15 in this process. We generated a
C2C12 myoblast subline that stably expresses H-2Kb-
EGFP (C2C12-Kb). As overexpression of H-2Kb impairs
myoblast differentiation in this study and [50], this co-
culture system is for myoblast and T cells. We then
transduced full-length OVA gene into C2C12-Kb myo-
blast as an endogenous antigen and generated C2C12-
Kb/OVA myoblast. TNF-α and IFN-γ greatly induced
the expression of IL-15 and H-2Kb on C2C12-Kb/OVA
cells (Fig. 5a). This high induction of H-2Kb might partly
result from the up-regulation of β2-microglobulin (B2m)
by the cytokines (Fig. 4b), because B2m is essential for
the stabilization of MHC class I molecule in correct con-
formation to receive the peptide in the ER and to move
from the ER to the cell surface [51]. The cytokine-
stimulated C2C12-Kb/OVA, but not C2C12-Kb, cells in-
duced production of granzyme B (grB) and IFN-γ by
memory-like OT-1 cells (Fig. 5b). We then found that an
IL-15Rβ-blocking antibody, but not IL-2-neutralizing
antibody, suppressed grB and IFN-γ production by the
memory-like OT-1 cells (Fig. 5c). As the cytokine-
stimulated C2C12-Kb/OVA cells were washed before co-
culturing with OT-1 cells in the presence of the exocytosis
inhibitor brefeldin A, IL-15 was presumably only present
on the muscle cell surface. These results indicate that
myoblasts stimulated with TNF-α and IFN-γ present anti-
gen and IL-15 to memory-like CD8+ T cells to promote
their effector function. Given that both myoblasts and
myotubes function as antigen-presenting cells under in-
flammation, what we observed in the myoblast-CD8+ T-
cell co-culture is likely applicable to myotubes.
Skeletal muscle IL-15 promotes the progression of auto-
immune myositis
TNF-α and IFN-γ are commonly expressed in the skeletal
muscle of patients suffering from inflammatory myop-
athies, in which CD8+ T cells infiltrate and play a critical
role in disease progression [23, 25, 52]. The enhancement
of memory-like CD8+ T-cell effector function by myoblast
IL-15 in vitro prompted us to examine the role of skeletal
muscle IL-15 in autoimmune myositis in vivo. We first
generated skeletal-muscle-specific Il15−/− mice by crossing
Il15f/f mice with ACTA-cre mice. The ACTA-Il15−/− mice
showed an 80 % reduction of Il15 mRNA specifically in
the skeletal muscle (Fig. 6a) with normal levels of IL-15/
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IL-15Rα complex and NK and memory CD8+ T cells in
the peripheral blood (Fig. 6b, c).
As two previously reported autoimmune myositis
models, wt mice immunized with C protein [38, 53] and
Syt7−/− mice [54, 55], did not develop myositis in our
hand, we immunized mice of Syt7−/− background with C
protein because impaired muscle membrane sealing due
to Syt7 deficiency facilitates myositis induction [54, 56].
Similar to previously reported pathology in auto-
immune myositis, we found that C-protein-immunized
Syt7−/−Il15f/f mice developed mononuclear cell infiltra-
tion (Fig. 6d). The mononuclear cells predominantly infil-
trated into the endomysium as well as the perimysium
and perivascular region (Fig. 6d (left)). The immunized
Syt7−/−Il15f/f mice also developed focal lymphatic invasion
of muscle fibers that features CD8+ T-cell-mediated myo-
sitis (Fig. 6d (middle)). Whereas C-protein-immunized
Syt7−/−ACTA-Il15−/− mice showed a significantly reduced
mononuclear cell infiltration and histopathology score
(Fig. 6d). We also found elevation of Cd4, Cd8α, and
F4/80 mRNA in the skeletal muscle of the immunized
Syt7−/−Il15f/f mice (Fig. 6e), suggesting infiltration of
CD4+ and CD8+ T cells and macrophages. The
expression of MHC class I subunit B2m; pro-
inflammatory cytokines Tnfa, Ifng, and Il1β: and ef-
fector molecule Prf1 were also induced in the skeletal
muscle of the immunized Syt7−/−Il15f/f mice (Fig. 6f ).
Whereas all these molecules examined were not induced
in the C-protein-immunized Syt7−/−ACTA-Il15−/− mice
(Fig. 6e, f ). These results together demonstrate that gen-
etic ablation of skeletal muscle IL-15 greatly reduced the
pathogenesis of autoimmune myositis.
Discussion
In this study, we examined the expression and function
of the skeletal muscle cell IL-15. We found that the IL-
15/IL-15Rα protein was not produced by skeletal muscle
cells under steady state conditions but highly induced by
TNF-α and IFN-γ and presented on the cell surface. Ra-
ther than being used by skeletal muscle cells, the IL-15
directly promoted the effector function of memory-like
CD8+ T cells in vitro and exacerbated the progression of
autoimmune myositis in vivo. These results suggest that
the endogenous IL-15 of the skeletal muscle cell func-
tions as an immune regulator in an inflammatory skel-
etal muscle microenvironment.
IL-15 has been reported to affect skeletal muscle
physiology, but IL-15 signaling in skeletal muscle cells
remains unclear. Our findings shed some light on this.
First, C2C12 and primary muscle cells expressed very
low levels of Il15rb mRNA and undetectable levels of
cell surface IL-15Rβ (Fig. 3a, b). Second, a soluble IL-15
hyperagonist, but not IL-15, induced STAT5 phosphoryl-
ation in C2C12 myotube at 100 ng/ml and above
(Fig. 3c). These concentrations are much higher than that
required for binding to IL-15Rβ/γc and the pg/ml level of
circulating the IL-15/IL-15Rα complex [9], which suggests
that the myotubes do not use soluble IL-15 or IL-15/IL-
15Rα complex under steady state conditions. Consistently,
our in vivo studies showed that IL-15 deficiency did not
affect skeletal muscle mass, cardiotoxin-induced muscle
regeneration, and compensatory hypertrophy of plantaris
muscle (Additional file 3, 5, and 6: Figure S2, S4, and S5).
Although trans-presentation of cell-bound IL-15/IL-15Rα
among the stimulated muscle cells may reach a high
enough local concentration to trigger signaling through
the sparsely expressed IL-15Rβ/γc, Il15 knockout did not
affect the response of the primary myotube to TNF-α and
IFN-γ in vitro (Fig. 4). Collectively, our results support
that the skeletal muscle cells do not use IL-15 for skeletal
muscle growth, regeneration, or inflammatory responses.
Our in vitro results appear different from previous in
vitro studies showing that exogenous IL-15 promotes
skeletal muscle hypertrophy [12, 14]. The difference may
partly result from the intrinsic differences between the
C2C12 and C2 cell lines used in this and previous stud-
ies, respectively. C2C12 cells have a higher differenti-
ation potency and insulin-like growth factor 1 (IGF-I)
level than C2 cells [57]. IGF-I is a strong stimulator for
muscle hypertrophy [58]. An earlier study indicates that
IL-15-induced C2 differentiation was only revealed in
the absence of IGF-I signaling [13]. Therefore, it is pos-
sible that the higher level of IGF-I masked IL-15-
induced hypertrophy in C2C12 cells under steady state
condition. However, IL-15 hyperagonist did not induce
STAT5 phosphorylation in TNF-α and IFN-γ-pretreated
(See figure on previous page.)
Fig. 5 Skeletal muscle cells presented antigen and provided IL-15 to promote the effector function of CD8+ T cells under TNF-α and IFN-γ treatment.
a Expression of IL-15 and H-2Kb on parental C2C12 and C2C12-Kb/OVA cells. Cells were treated with TNF-α and IFN-γ (TNF + IFN) or without (Control)
for 24 h, stained with anti-IL-15 or anti-H-2Kb antibody, then analyzed by flow cytometry. “Unstained” indicates C2C12 or C2C12-Kb/OVA myoblast
without antibody staining. b Expression of grB and IFN-γ by CD8+ T cells co-cultured with cytokine-treated C2C12-Kb or C2C12-Kb/OVA myoblasts for
8 h. After co-culture, CD8+ T cells were stained with anti-grB and IFN-γ antibody by intracellular staining then analyzed by flow cytometry. Data are
representative of three independent experiments with similar results. c Effect of anti-IL-2 (αIL-2, S4B6) or anti-IL-2/15Rβ (αRβ, TM-β1) antibody on grB
and IFN-γ production by CD8+ T cells co-cultured with TNF + IFN-pretreated C2C12-Kb/OVA myoblasts. The percentages of grB+ and IFN-γ+ cells in
CD8+ T cells are indicated in the dot plots. Data from independent experiments were compiled as % normalized activation using the percentage of
grB+ or IFN-γ+ cells in CD8+ T cells of the TNF + IFN-pretreated C2C12-Kb/OVA cell co-culture group of each experiment as 100 % (bottom panels).
Isotype controls, Rat IgG2a (Iso) and Rat IgG2b (Iso). Each symbol is representative of one independent experiment. **p < 0.01, ***p < 0.001
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myotubes (Fig. 3e), in which 90 % of endogenous IGF-I
was downregulated [59]. Therefore, the scanty amount
of IL-15Rβ likely limits the use of IL-15 by the muscle
cells.
Although various IL-15 functions in the skeletal
muscle were reported previously, some controversial re-
sults exist between those in vitro and in vivo studies. In
contrast to muscle hypertrophy induced by IL-15 in
vitro, muscle atrophy was observed in mice carrying
skeletal-muscle-specific IL-15 transgene [18] or receiving
systemic infusion of exogenous IL-15 [19]. The muscle
atrophy may be contributed by fatal leukemia [60] and
metabolic dysregulation [61] induced by overexpression
of IL-15 . In addition, recent studies show that exercise
endurance increases in skeletal-muscle-specific Il15-trans-
genic mice and reduces in Il15−/− mice [18, 20], despite
that their earlier ex vivo study found no difference in the
fatigue index between the EDL or soleus muscle isolated
from Il15−/− mice and skeletal-muscle-specific Il15-trans-
genic mice [21]. Collectively, the inconsistency between
the in vitro/ex vivo and in vivo results suggests that the
change of muscle mass or exercise endurance in vivo is
not caused by the direct effect of IL-15 on the skeletal
muscle.
IL-15 has been reported to be involved in a number of
autoimmune diseases, including rheumatoid arthritis, in-
flammatory bowel disease, and multiple sclerosis, in
which IL-15 promotes the effector function of cytotoxic
CD8+ T cells to destroy the target tissues [62]. Consider-
ing that TNF-α and IFN-γ induced the expression of IL-
15/IL-15Rα and T-cell interacting molecules in skeletal
muscle cells, the stimulated muscle cells may directly
communicate with T cells. Indeed, we clearly demon-
strated in vitro that the stimulated skeletal muscle cells
presented antigen and IL-15 to memory-like CD8+ T cells
and enhanced their effector function. Following induction
of autoimmune myositis in vivo, skeletal-muscle-specific
Il15−/− mice showed reduced mononuclear cell infiltra-
tion, histopathology score, and expression of inflammatory
molecules. Our data together suggest a scenario in which
skeletal muscle IL-15 promotes the production of cyto-
toxic molecules, such as granzyme, by memory CD8+ T
cells to necrotize muscle cells, which triggers phagocyte
recruitment and inflammation. The locally enriched cyto-
kines, TNF-α and IFN-γ (Fig. 6f), may stimulate IL-15 ex-
pression by muscle cells to form a feed-forward loop to
perpetuate the inflammatory milieu, which contributes to
the progression of autoimmune myositis.
Conclusions
We provide new insights into the function of skeletal
muscle IL-15. Rather than being used by the muscle cell
itself, the skeletal muscle IL-15 directly promotes the ef-
fector function of memory-like CD8+ T cells, which fa-
cilitates the formation of a pro-inflammatory skeletal
muscle microenvironment during myositis progression.
Given that IL-15 is not required for muscle growth and
regeneration, IL-15 has the potential to be a suitable
therapeutic target for autoimmune myositis.
Additional files
Additional file 1: Table S1. Primer pairs used in this study.
Additional file 2: Figure S1. IL-1α/β or LPS induced moderate
expression of IL-15/IL-15Rα protein complex in C2C12 myotubes. (A–C)
C2C12 myotubes were treated with IFN-α (0 or 10 ng/ml), IL-1α/β (0 or
10 ng/ml), or LPS (0, 0.1, or 1 μg/ml) and examined for the expression of
Il15 and Il15ra mRNA at indicated time points. Data represent mean ±
SEM of triplicates. (D–F) The level of IL-15/IL-15Rα complex protein in cell
lysate and culture medium after 24-h treatment with IL-1α/β, LPS, or IL-1α
were measured by ELISA. Data were pooled from two and three independent
experiments. Data are mean ± SEM. *p< 0.05, **p< 0.01, ***p< 0.001, in
comparison to “0” or “con”.
Additional file 3: Figure S2. Phenotype analysis of 12-week-old male
wt, Il15−/−, and Il15ra−/− mice. (A) Body weight. (B) Absolute weight and
the percentage of body weight (% BW) of heart and gonadal fat pad. (C)
Absolute weight and the value normalized to tibia bone length (mg/
mm) of gastrocnemius muscle (Gas), tibialis anterior muscle (TA), soleus
muscle (Sol), and EDL. One symbol represents one mouse. wt (n = 14);
Il15−/− (n = 12); Il15ra−/− (n = 13).
Additional file 4: Figure S3. Comparative analysis of wt and Il15−/−
primary myoblast differentiation. (A) Morphology of wt and Il15−/−
primary myotubes after differentiation for 2 days. The images are
representative of at least three independent experiments. (B) Fusion
(See figure on previous page.)
Fig. 6 Skeletal muscle IL-15 contributes to the progression of autoimmune myositis. a The expression of Il15 mRNA in various tissues of wt (n = 3),
Il15f/f (n = 5), and ACTA-Il15−/− (n = 5) mice was detected by qPCR. WAT white adipose tissue. Data are mean ± SEM. ***p < 0.001. b The amount of IL-
15/IL-15Rα complex protein in the serum of Il15f/f and ACTA-Il15−/− mice (n = 9–10) was measured by ELISA. Data are mean ± SEM. c Comparison of
memory CD8+ T cell (mCD8) and NK cell (NK) level in the peripheral blood among wt, Il15−/−, Il15f/f, and ACTA-Il15−/− mice (n = 5 in each group). Fold
change was calculated by normalizing the percentage of indicated cell type in mutant mice to that in wt mice. mCD8 were H57+CD19−CD8
+CD44hiCD122hi, and NK were H57−CD19−NK1.1+. Data are mean ± SEM. ***p < 0.001. d Mononuclear cell infiltration in the quadriceps muscles of Syt7
−/−Il15f/f and Syt7−/−ACTA-Il15−/− mice 14 days after C protein immunization (Left). Mononuclear cell infiltration was found in the endomysium (black
square), perimysium (black arrowhead), and perivascular region (white arrowhead). Focal lymphatic invasion of myofibers were observed in C-protein-
immunized Syt7−/−ACTA-Il15−/− mice as indicated by the white arrowhead (Middle). The histopathology scores were compiled in the right panel with
each symbol representing one mouse (Right). Scale bar in left = 100 μm; middle = 25 μm. **p < 0.01. e Expression of mononuclear cell markers, Cd4,
Cd8, and F4/80, mRNA in the quadriceps muscles of C-protein-immunized mice measured by qPCR. Each symbol representing one mouse. *p < 0.05,
**p < 0.01. f Expression of immune-relevant genes mRNA in the quadriceps muscles of C-protein-immunized mice measured by qPCR. Each symbol
representing one mouse. *p < 0.05, **p < 0.01
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index and differentiation index of wt and Il15−/− primary myoblast. Fusion
index is the percentage of nuclei in MyHC-positive cells among total nuclei.
Differentiation index is the percentage of myotubes with indicated number
of nuclei among total myotubes. Each index was calculated from at least 24
microscopic fields with each field containing more than 10 myotubes. Data
are mean ± SEM. (C) Expression of differentiation-related genes in
primary muscle cells. Samples were collected after culturing in
growth medium for 24 h (GM) and after switching into differentiation
medium for 1 and 2 days (day 1 and 2). Data are mean ± SEM. Data
are pooled from three independent experiments.
Additional file 5: Figure S4. Cardiotoxin-induced muscle regeneration
in the TA muscle of wt and Il15−/− mice. TA muscle was injected
intramuscularly with cardiotoxin (50 μl, 10 μM, Sigma), dissected out, and
fixed in formalin at days 5, 10, and 21 after injection. Fixed muscles were
embedded in paraffin for histological examination. (A) Representative
images of TA muscle histology after cardiotoxin injection for 5 (n = 4
each genotype), 10 (n = 4 each genotype), and 21 (wt n = 2; Il15−/− n = 3)
days. Muscle fibrosis was evaluated by Masson’s trichrome staining in the
21-day cardiotoxin-injected samples. (B) Expression profiling of
regeneration-related genes in the TA muscle injected with cardiotoxin for
5 and 10 days using qPCR. Each group contains four mice. Scale bar =
50 μm. Data are mean ± SEM. *p < 0.05, ***p < 0.001.
Additional file 6: Figure S5. Compensatory hypertrophy of plantaris
muscle. Lower leg soleus and gastrocnemius muscles were removed
without damaging the neurovascular supply. Fourteen days after surgery,
plantaris muscles were dissected out and weighted. No body weight
change was observed during the experiment. The weight of plantaris
muscle of mice received surgery or sham surgery were normalized to
body weight. One symbol represents one mouse. ***p < 0.001.
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